Addus HomeCare vs National HealthCare
ADUS and NHC side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ADUS and NHC compare
National HealthCare is the larger company, worth 1.4 times as much as Addus HomeCare ($3.2B against $2.3B).
On earnings, Addus HomeCare is cheaper: it trades at 21.3× trailing earnings, against 23.1× for National HealthCare.
Addus HomeCare grew revenue faster over the last twelve months (15.9% versus 6.9% for National HealthCare).
National HealthCare keeps more of each dollar of sales as profit, with a net margin of 9.0% compared with 7.1% at Addus HomeCare.
National HealthCare pays a dividend yielding 1.3%; Addus HomeCare does not pay one.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ADUS | NHC |
|---|---|---|
| Size and price | ||
| Market cap | $2.3B | $3.2B |
| Share price | $121.56 | $205.77 |
| Change, 1 year | 11.5% | 60.6% |
| Change, 5 years | 33.0% | 207% |
| Beta (5Y) | 0.28 | −0.25 |
| Employees | 5,290 | 15K |
| StockData Score | ||
| Total score | 20 | 20 |
| Valuation score | 5 (better) | 2 |
| Growth score | 4 (better) | 3 |
| Performance score | 5 | 5 |
| Health score | 6 | 6 |
| Dividend score | 0 | 4 (better) |
| Valuation | ||
| P/E | 21.3× (better) | 23.1× |
| P/S | 1.5× (better) | 2.1× |
| P/B | 2.0× (better) | 2.9× |
| EV/EBITDA | 13.5× (better) | 16.8× |
| P/FCF | 14.7× (better) | 22.0× |
| PEG | 0.95 | 0.31 (better) |
| FCF yield | 6.8% (better) | 4.5% |
| Fair value | $137.11 | $171.46 |
| Margin of safety | 11.3% (better) | −20.0% |
| Growth | ||
| Revenue growth (TTM) | 15.9% (better) | 6.9% |
| Revenue growth, 5Y average | 13.2% (better) | 8.1% |
| Net income growth (TTM) | 26.9% | 33.8% (better) |
| EPS growth (TTM) | 25.8% | 32.5% (better) |
| EPS growth, 5Y average | 20.2% | 23.0% (better) |
| Profitability | ||
| Gross margin | 32.4% | – |
| Operating margin | 10.0% (better) | 9.3% |
| Net margin | 7.1% | 9.0% (better) |
| FCF margin | 10.5% (better) | 9.4% |
| Return on equity | 9.7% | 13.1% (better) |
| Return on invested capital | 10.0% | 10.6% (better) |
| Financial health | ||
| Debt / equity | 0.05 (better) | 0.00 |
| Net debt / EBITDA | −0.23 | −0.21 |
| Interest coverage | 14.9× | 56.6× (better) |
| Current ratio | 1.69 | 1.86 (better) |
| Altman Z-score | 6.37 | 7.02 (better) |
| Piotroski F-score | 6 | 6 |
| Dividends and buybacks | ||
| Dividend yield | – | 1.3% |
| Payout ratio | – | 28.4% |
| Years of dividend growth | – | 12 |
| Dividend growth, 5Y average | – | 4.0% |
| Buyback yield | – | 0.15% |
| Shareholder yield | 0.00% | 1.4% (better) |
| Ownership | ||
| Held by institutions | 104% | 65.3% |
| Held by insiders | 2.8% | 9.3% |
| Insider net buying, 12 months | −$20.7M | −$9.1M (better) |
| Short interest, % of float | 5.5% | 5.4% |
Go deeper
- ADUS stock overview
- ADUS income statement
- ADUS valuation and score
- NHC stock overview
- NHC income statement
- NHC valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.